Equities Analysts Issue Forecasts for ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at Roth Capital reduced their FY2024 earnings per share estimates for shares of Zevra Therapeutics in a research note issued on Tuesday, November 12th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($1.95) per share for the year, down from their previous estimate of ($1.57). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.38) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.31) EPS, FY2026 earnings at $0.67 EPS, FY2027 earnings at $1.41 EPS and FY2028 earnings at $1.85 EPS.

Other equities analysts also recently issued research reports about the company. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Guggenheim assumed coverage on Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 target price for the company. Canaccord Genuity Group reduced their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday. Maxim Group increased their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $8.62 on Friday. The company has a market capitalization of $453.57 million, a price-to-earnings ratio of -4.38 and a beta of 1.93. Zevra Therapeutics has a fifty-two week low of $4.18 and a fifty-two week high of $9.21. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The business’s 50-day moving average is $8.03 and its 200-day moving average is $6.49.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. During the same quarter in the previous year, the firm posted ($0.15) EPS.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently modified their holdings of ZVRA. Barclays PLC increased its holdings in Zevra Therapeutics by 292.6% in the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock worth $399,000 after purchasing an additional 42,926 shares in the last quarter. XTX Topco Ltd acquired a new stake in Zevra Therapeutics during the third quarter worth approximately $94,000. State Street Corp grew its stake in Zevra Therapeutics by 7.4% in the third quarter. State Street Corp now owns 772,825 shares of the company’s stock valued at $5,363,000 after acquiring an additional 52,966 shares during the period. Vestal Point Capital LP acquired a new stake in Zevra Therapeutics in the third quarter valued at approximately $3,644,000. Finally, Stonepine Capital Management LLC acquired a new stake in Zevra Therapeutics in the third quarter valued at approximately $4,858,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.